Generic Drugs Stocks Technical Reports -- Mylan, Horizon Pharma, Allergan, and Akorn

Sep 02, 2016, 07:40 ET from Chelmsford Park SA

NEW YORK, September 2, 2016 /PRNewswire/ --

Rising costs of brand-name medicines continue to drive more and more consumers to settle for the much cheaper Generic Drugs. This morning, presents four stocks within the Generic Drugs space for review, one of which has dominated the headlines just recently. Let us take a look at our featured companies: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Akorn Inc. (NASDAQ: AKRX).  Download the free research reports on these stocks today:


Hertfordshire, the UK-based Mylan N.V.'s shares fell 1.04%, closing Thursday's trading session at $41.92. The stock recorded a trading volume of 5.69 million shares, which was above its three months average volume of 5.29 million shares. Shares of the Company are trading 8.59% below their 50-day moving average. Additionally, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide, have a Relative Strength Index (RSI) of 27.99.

On September 1st, 2016, Mylan announced that the U.S. Patent and Trademark Office has ruled in favor of Mylan in its inter parties review proceeding and found all claims of U.S. Patent No. 8,969,302, which is owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd., unpatentable. See our free and comprehensive research report on MYL at:

Horizon Pharma  

On Thursday, shares in Dublin, Ireland headquartered Horizon Pharma PLC recorded a trading volume of 1.75 million shares. The stock dropped 0.96%, ending the day at $18.62. The Company's shares have advanced 4.55% in the previous three months. The stock is trading above its 200-day moving average by 2.72%. Furthermore, shares of Horizon Pharma, which engages in identifying, developing, acquiring, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the US and internationally, have an RSI of 37.06.

On August 18th, 2016, Horizon Pharma announced that the US Patent and Trademark Office has granted a Notice of Allowance for US patent application number 14/563,000, entitled "Delayed-Release Glucocorticoid Treatment of Rheumatoid Disease" that covers Horizon's U.S. approved medicine RAYOS (prednisone) delayed-release tablets. The Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed.  After issuance, Horizon plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. HZNP free research report PDF is just a click away at:


Dublin, Ireland headquartered Allergan PLC's stock finished the day 1.37% higher at $237.76 and with a total volume of 2.82 million shares traded. Shares of the Company, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, are trading below their 50-day moving average by 2.57%. The stock has an RSI of 39.22.

On August 19th, 2016, research firm Mizuho upgraded the Company's stock rating from 'Neutral' to 'Buy'. The research firm also revised upwards its previous target price from $248 to $318.

On August 31st, 2016, Allergan announced that its subsidiaries Forest Laboratories, LLC, Forest Laboratories Holdings, Ltd. and Allergan USA, along with Adamas Pharmaceuticals, Inc. (ADMS), have entered into a settlement agreement with Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC. The settlement relates to a patent infringement litigation brought by Forest and Adamas in response to Amneal's abbreviated new drug application (ANDA) seeking approval to market generic versions of Allergan's NAMZARIC® (memantine and donepezil hydrochlorides) extended-release, a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor, AChEI). Sign up for your complimentary report on AGN at:


Shares in Lake Forest, Illinois headquartered Akorn Inc. ended yesterday's session 0.89% lower at $26.68 and with a total volume of 1.01 million shares traded. The stock is trading 8.10% below its 200-day moving average. Shares of the Company, which develops, manufactures, and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter consumer health products and animal health pharmaceuticals in the US and internationally, have an RSI of 30.70.

On August 4th, 2016, Akorn reported revenue of $281 million for Q2 2016, a 27% increase from Q2 2015. The company's GAAP net income for Q2 2016 was $62 million, or $0.50 per diluted share, up 85% compared to GAAP net income of $33 million, or $0.27 per diluted share, in Q2 2015.

On August 05th, 2016, research firm WallachBeth reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $39 a share to $40 a share. Register for free on and download the latest research report on AKRX at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA